Research programme: thrombosis therapy - Mitsubishi Tanabe Pharma

Drug Profile

Research programme: thrombosis therapy - Mitsubishi Tanabe Pharma

Alternative Names: TA-7182; Thrombosis therapy research programme - Mitsubishi Tanabe Pharma

Latest Information Update: 27 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tanabe Seiyaku
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 27 May 2010 Discontinued - Preclinical for Thrombosis in Japan (unspecified route)
  • 18 Jul 2005 This programme is available for licensing outside Japan (
  • 18 Jul 2005 Preclinical trials in Thrombosis in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top